Biosimilar challenges include complex manufacturing processes and regulatory obstacles, offset by less regulated market ...

Bio-Thera Solutions, the developer of the biosimilar, will continue to hold manufacturing rights in the US market.

Originally approved by the FDA in September 2023, Biogen's Tofidence became the first tocilizumab biosimilar available in the ...

Organon’s workforce cuts come several months after the company’s loss of exclusivity to its second-largest product, Atozet.

Organon (OGN) stock in focus as the Merck (MRK) spinoff buys rights to Biogen's (BIIB) biosimilar Tofidence, targeting ...

New Jersey Democratic Sen. Cory Booker has carried an all-night speech in protest of President Donald Trump’s agenda into a ...

Tofidence is indicated in certain patients for the treatment of moderate to severe rheumatoid arthritis, giant cell arteritis ...

Organon (OGN) announced that it has acquired from Biogen (BIIB) regulatory and commercial rights in the U.S. for Tofidence, a biosimilar to ...

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help journalists and consumers stay on top of the week's most newsworthy and ...

Iowa’s Republican attorney general is suing a county sheriff over his Facebook post saying his department doesn’t always need ...

Organon (OGN) closed the latest trading day at $15.39, indicating a -1.35% change from the previous session's end. The stock's performance was behind the S&P 500's daily gain of 0.08%. Elsewhere ...

SEATTLE, WA, USA I March 21, 2025 I Omeros Corporation (Nasdaq: OMER) today reported that clinical trial site activation for enrollment is underway for the company’s Phase 3 program evaluating ...